IRIS Accounts Production v24.2.0.383 13462641 director 1.7.23 30.6.24 30.6.24 false true false false true false Ordinary A Shares 1.00000 Ordinary B Shares 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh134626412023-06-30134626412024-06-30134626412023-07-012024-06-30134626412022-06-30134626412022-07-012023-06-30134626412023-06-3013462641ns15:EnglandWales2023-07-012024-06-3013462641ns14:PoundSterling2023-07-012024-06-3013462641ns10:Director12023-07-012024-06-3013462641ns10:PrivateLimitedCompanyLtd2023-07-012024-06-3013462641ns10:SmallEntities2023-07-012024-06-3013462641ns10:AuditExempt-NoAccountantsReport2023-07-012024-06-3013462641ns10:SmallCompaniesRegimeForDirectorsReport2023-07-012024-06-3013462641ns10:SmallCompaniesRegimeForAccounts2023-07-012024-06-3013462641ns10:FullAccounts2023-07-012024-06-3013462641ns10:OrdinaryShareClass12023-07-012024-06-3013462641ns10:OrdinaryShareClass22023-07-012024-06-3013462641ns10:RegisteredOffice2023-07-012024-06-3013462641ns5:CurrentFinancialInstruments2024-06-3013462641ns5:CurrentFinancialInstruments2023-06-3013462641ns5:ShareCapital2024-06-3013462641ns5:ShareCapital2023-06-3013462641ns5:RetainedEarningsAccumulatedLosses2024-06-3013462641ns5:RetainedEarningsAccumulatedLosses2023-06-3013462641ns5:ComputerEquipment2023-07-012024-06-3013462641ns5:ComputerEquipment2023-06-3013462641ns5:ComputerEquipment2024-06-3013462641ns5:ComputerEquipment2023-06-3013462641ns5:WithinOneYearns5:CurrentFinancialInstruments2024-06-3013462641ns5:WithinOneYearns5:CurrentFinancialInstruments2023-06-3013462641ns10:OrdinaryShareClass12024-06-3013462641ns10:OrdinaryShareClass22024-06-30
REGISTERED NUMBER: 13462641 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2024

FOR

LAWRENCE L PHARMA LIMITED

LAWRENCE L PHARMA LIMITED (REGISTERED NUMBER: 13462641)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


LAWRENCE L PHARMA LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 30 JUNE 2024







DIRECTOR: S K Leung





REGISTERED OFFICE: Rae House
Dane Street
Bishops Stortford
Herts
CM23 3BT





BUSINESS ADDRESS: 50 Charteris Road
Woodford Green
Essex
IG8 0AS





REGISTERED NUMBER: 13462641 (England and Wales)





ACCOUNTANTS: Barrow LLP
Rae House
Dane Street
Bishops Stortford
Herts
CM23 3BT

LAWRENCE L PHARMA LIMITED (REGISTERED NUMBER: 13462641)

BALANCE SHEET
30 JUNE 2024

30.6.24 30.6.23
Notes £    £   
FIXED ASSETS
Tangible assets 5 1,573 590

CURRENT ASSETS
Debtors 6 698 7,889
Cash at bank and in hand 226,559 145,145
227,257 153,034
CREDITORS
Amounts falling due within one year 7 (108,704 ) (87,144 )
NET CURRENT ASSETS 118,553 65,890
TOTAL ASSETS LESS CURRENT LIABILITIES 120,126 66,480

PROVISIONS FOR LIABILITIES (393 ) (148 )
NET ASSETS 119,733 66,332

CAPITAL AND RESERVES
Called up share capital 8 100 100
Retained earnings 119,633 66,232
SHAREHOLDERS' FUNDS 119,733 66,332

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit And Loss and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 10 October 2024 and were signed by:





S K Leung - Director


LAWRENCE L PHARMA LIMITED (REGISTERED NUMBER: 13462641)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

1. STATUTORY INFORMATION

Lawrence L Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 25% on cost

Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instruments.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes, in effect, a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Other financial instruments are initially recognised at fair value, unless payment for an asset is deferred upon normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit And Loss and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


LAWRENCE L PHARMA LIMITED (REGISTERED NUMBER: 13462641)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 JUNE 2024

3. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

4. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 3 ) .

5. TANGIBLE FIXED ASSETS
Computer
equipment
£   
COST
At 1 July 2023 833
Additions 1,203
At 30 June 2024 2,036
DEPRECIATION
At 1 July 2023 243
Charge for year 220
At 30 June 2024 463
NET BOOK VALUE
At 30 June 2024 1,573
At 30 June 2023 590

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.6.24 30.6.23
£    £   
Other debtors 698 7,889

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.6.24 30.6.23
£    £   
Trade creditors - 89
Taxation and social security 35,116 21,785
Other creditors 73,588 65,270
108,704 87,144

LAWRENCE L PHARMA LIMITED (REGISTERED NUMBER: 13462641)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 JUNE 2024

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30.6.24 30.6.23
value: £    £   
60 Ordinary A Shares £1 60 60
40 Ordinary B Shares £1 40 40
100 100